Board of Directors
Andrew Denver BSc (Hons), MBA, FAICD
Chairman
Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation, with responsibility for all Pall Corporation activities in the Asia Pacific region.
Andrew joined Pall in 2002 with the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was President. Andrew was appointed President and Chief Operating Officer of the US Filter Filtration and Separations Group in February 1998 after US Filter acquired Memtec Limited. Prior to his position at US Filter, Andrew was President and Chief Operating Officer of Memtec Limited from 1987 to 1997, and prior to that, at Baxter Healthcare Corporation where he was employed for 12 years in a number of positions. Andrew’s last assignment at Baxter Healthcare Corporation was as President of the corporation’s US based Medical Devices Division.
Andrew is a foundation member of The Principals Funds Management Pty Ltd, which helps Australian technology businesses commercialise their technologies. Andrew was a founding member and director of the Australian Environment Management Export Corporation and was the inaugural chairman for the first two years. Andrew was also a founding member and director of the Environment Management Industry Association of Australia. Andrew is a non executive director of CathRx Ltd, Anzon Australia Ltd, Cochlear Ltd and Universal Biosensors Inc.
Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors. Andrew was appointed as a Director of SpeeDx Pty Ltd in 2009.
Andrew Jane BSc (Hons), MSc
Non Executive Director
Andy is a Partner with CM Capital Investments in Brisbane, Australia. CM Capital was founded in 1999 and is one of the leading Institutional VC firms in Australia with $250m under management and 20 active portfolio companies. CM. He is currently a Board Member of Universal Biosensors Inc (ASX listed), Advent Pharmaceuticals, Pty., SpeeDx Pty., Piedmont Pharmaceuticals Inc and Altiris Therapeutics, Inc. He is also an Observer to the Board of Osprey Medical,Inc.
Andy has more than 20 years of experience in the biomedical and IT industries. Following 4 years as a Project Manager at the CSIRO, Andy spent 5 years at AGEN Biomedical, where he was responsible for the company's instrumentation and biosensor program and later for the primary business planning and management of the Thromboview™ biopharmaceutical imaging project. He joined Lake Technology, Sydney, in 1999, prior to its ASX listing, as Director of Business Development & Licensing, where he was instrumental in the worldwide business development and marketing of Dolby Headphone™ and Dolby Virtual Speaker™ technologies which have since been adopted by leading brand consumer electronics companies, mobile phone and PC companies. Lake Technology was acquired by Dolby Labs in 2003.
He holds a BSc Hons in Physics from the University of St Andrews, Scotland and a MSc in Biomedical Instrumentation & Analytical Science from the University of Manchester (UMIST).
John E. Klopp BS MS
Non Executive Director
John Klopp was Worldwide Vice President, Business Development, for Johnson & Johnson’s Diabetes Care Franchise when he retired in 2009. During his sixteen year career with J&J, he established several partnerships with other companies, led the acquisition of two publicly traded companies, and led several successful patent legal actions. The acquisitions represented over 90% of the Diabetes Care Franchise sales in 2009.
Prior to Johnson & Johnson, he was Manager of Licenses and Acquisitions for DuPont Medical Products Department. During his 28 year career with DuPont, he held positions of increasing responsibility in New Venture Development, turnarounds, partnership and joint venture development, and M&A. After the formation of a joint venture with Applied BioTechnology (Inc.), he was elected to the Board of ABT.
In 2010, he was appointed to the Research and Development Committee of the Juvenile Diabetes Research Foundation. He received B.S. and M.S. degrees in Chemical Engineering from Oklahoma State University. John was appointed as a Director of SpeeDx Pty Ltd in 2010.
|
